IMMUNOBIOLOGY OF CLASS IB MOLECULES
IB 类分子的免疫生物学
基本信息
- 批准号:6089802
- 负责人:
- 金额:$ 32.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-04-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class I antigen T cell receptor antigen presentation autoantigens bacterial antigens cytotoxic T lymphocyte flow cytometry gene expression genetically modified animals laboratory mouse major histocompatibility complex natural killer cells polymerase chain reaction protein engineering receptor expression tissue /cell culture
项目摘要
The identification and characterization of MHC linked class Ib loci has proven to be a exciting area of investigation. Studies from our laboratory and others have shown that class Ib molecules can function to present peptide and non-peptide epitopes to T cells. Several class Ib molecules have been implicated in the immune response to intracellular bacterial pathogens and mouse/human counterparts have been identified. Furthermore, class Ib molecules have also been found to serve as ligands for NK cells. This information indicates that this subset of MHC class I molecules have evolved to play key roles in the immune process. We propose to design a new murine model for the analysis of mouse and human class Ib function. We will engineer, characterize and express a single chain Qa-1b class Ib molecule as a transgene in class I deficient mice. This mouse model will allow the definition of the role for Qa-1 in the selection of the T cell repertoire. Also we will be able to examine the range of pathogens for which Qa-1 restricted CD8+ effector cells are evoked. We will investigate the role of Qa-1 as a ligand for inhibitory receptors expressed on NK cells as well as CD8+ T cells. We hypothesize that Qa-1 has unique structural features that allow it to both serve as a ligand for both NK receptors and antigen-specific T cell receptors. Lastly, we propose to study the structure of endogenous self-peptides bound to Qa-1 and the physical/chemical definition of ligand binding to Qa- 1. Such studies will allow us to fully understand the peptide features requisite for interaction with the Qa-1 binding site. These studies will not only lend insight into the role of Qa- 1 in the presentation of self peptides to alloreactive T cells, but also facilitate the identification of bacterial and/or TCR/Ig derived peptides presented by Qa-1 to regulatory CD8+ T cells. Also, novel antigen presentation pathways may be revealed. Collectively such studies will provide the basic principles needed for our long term objective, to utilize this novel family of non-polymorphic class I molecules as targets for vaccine strategies and/or immune modulation.
MHC连锁的Ib类基因座的鉴定和表征已被证明是一个令人兴奋的研究领域。我们实验室和其他实验室的研究表明,Ib类分子可以向T细胞呈递肽和非肽表位。几种Ib类分子涉及对细胞内细菌病原体的免疫应答,并且已经鉴定了小鼠/人对应物。此外,还发现Ib类分子用作NK细胞的配体。这一信息表明,MHC I类分子的这一子集已经进化到在免疫过程中发挥关键作用。我们建议设计一种新的小鼠模型,用于分析小鼠和人的Ib类功能。我们将在I类缺陷小鼠中设计、表征和表达单链Qa-1b Ib类分子作为转基因。该小鼠模型将允许定义Qa-1在T细胞库选择中的作用。我们还将能够检查诱发Qa-1限制性CD 8+效应细胞的病原体的范围。我们将研究Qa-1作为NK细胞以及CD 8 + T细胞上表达的抑制性受体的配体的作用。我们假设Qa-1具有独特的结构特征,使其能够同时作为NK受体和抗原特异性T细胞受体的配体。 最后,我们建议研究与Qa-1结合的内源性自身肽的结构和与Qa- 1结合的配体的物理/化学定义。这些研究将使我们能够充分了解与Qa-1结合位点相互作用所需的肽特征。这些研究不仅有助于深入了解Qa- 1在向同种异体反应性T细胞呈递自身肽中的作用,而且有助于鉴定由Qa-1呈递给调节性CD 8 + T细胞的细菌和/或TCR/IG衍生肽。此外,新的抗原呈递途径可能被揭示。总的来说,这些研究将提供我们长期目标所需的基本原理,以利用这种新型的非多态性I类分子家族作为疫苗策略和/或免疫调节的靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark J Soloski其他文献
Mark J Soloski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark J Soloski', 18)}}的其他基金
"Innate Immune Lymphocytes and the Gut Epithelium"
“先天免疫淋巴细胞和肠上皮”
- 批准号:
7860355 - 财政年份:2009
- 资助金额:
$ 32.48万 - 项目类别:
"Innate Immune Lymphocytes and the Gut Epithelium"
“先天免疫淋巴细胞和肠上皮”
- 批准号:
7707042 - 财政年份:2009
- 资助金额:
$ 32.48万 - 项目类别:
Identification of Immune Targets in Psoriatic Arthritis
银屑病关节炎免疫靶点的鉴定
- 批准号:
7674130 - 财政年份:2008
- 资助金额:
$ 32.48万 - 项目类别:
Innate Cellular Elements and Enteric Bacterial Infection
先天细胞元件和肠道细菌感染
- 批准号:
7140557 - 财政年份:2005
- 资助金额:
$ 32.48万 - 项目类别:
相似海外基金
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 32.48万 - 项目类别:
Discovery Projects
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 32.48万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 32.48万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 32.48万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 32.48万 - 项目类别: